Greatest EGFR Prevalence in Women with Adenocarcinoma with No Smoking History
the Cancer Therapy Advisor take:
Women diagnosed with adenocarcinoma who never smoked demonstrated the greatest prevalence of epidermal growth factor receptor (EGFR) mutations, according to an article published online in the journal Cancer Epidemiology, Biomarkers & Prevention.
The study included an initial dataset of 4,200 patients. In total, 4,196 of these participants were eligible—431 of which had EGFR mutations.
Results showed women had significantly greater (P <0.0001) odds of EGFR mutations compared to males (OR: 1.85; 95% C: 1.48, 2.32).
A similar trend was observed for never-smokers versus smokers (OR, 3.64; 95% CI: 2.91, 4.56), and patients with adenocarcinoma versus other histologic subtypes (OR, 2.94; 95% CI: 2.17, 4.08).
Furthermore, EGFR tyrosine kinase inhibitors (TKIs) in EGFR mutation–positive non-small cell lung cancer (NSCLC) and combination chemotherapy in EGFR mutation–negative NSCLC were determined to be the most commonly prescribed first-line systemic treatments (56.6% and 78.5%, respectively).
Women diagnosed with adenocarcinoma who never smoked demonstrated the greatest prevalence of epidermal growth factor receptor (EGFR) mutations.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Increased Body Mass Index May Be Predictive of Recurrence, Progression in Bladder Cancer
- Aspirin, Non-Aspirin NSAID-Use May Improve Survival Outcomes in Ovarian Cancer
- Research Indicates Imatinib Is Effective in Pediatric Patients With Chronic Phase CML
- Ribociclib FDA-Approved For Additional Indications in HR+, HER2- Advanced Breast Cancer
- Research Advances for Mutant KRAS-Driven Lung Adenocarcinoma